HbA1c Testing Device Market Size, Share, Growth, and Industry Analysis, By Type (Point-of-care (POC) Testing Devices,Laboratory-based Testing Devices), By Application (Hospital,Homecare,Other), Regional Insights and Forecast to 2035

HbA1c Testing Device Market Overview

The global HbA1c Testing Device Market size is projected to grow from USD 158.1 million in 2026 to USD 172.19 million in 2027, reaching USD 340.79 million by 2035, expanding at a CAGR of 8.91% during the forecast period.

The HbA1c testing device market is experiencing significant growth, driven by the increasing global prevalence of diabetes and the growing emphasis on early diagnosis and long-term disease management. More than 537 million adults were living with diabetes in 2021, with the number expected to rise to 643 million by 2030, creating sustained demand for reliable HbA1c testing solutions. Nearly 79% of adults with diabetes reside in low- and middle-income countries, accelerating the need for affordable and accessible diagnostic technologies. Additionally, diabetes-related complications account for over 1.5 million deaths annually, highlighting the importance of routine HbA1c monitoring. More than 60% of healthcare facilities worldwide have incorporated HbA1c testing into regular clinical practice, supporting the widespread adoption of both laboratory-based and point-of-care testing devices.

The United States represents one of the largest markets for HbA1c testing devices, supported by its substantial diabetic population and advanced healthcare infrastructure. Around 37.3 million people were living with diabetes in 2022, representing 11.3% of the country's population, while nearly 96 million adults were estimated to have prediabetes. Over 85% of healthcare providers utilize HbA1c testing for long-term glucose monitoring in line with established clinical guidelines. Furthermore, approximately 1.4 million new diabetes cases are diagnosed annually, driving continued demand for HbA1c testing across hospitals, diagnostic laboratories, physician offices, and homecare settings.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 65% of healthcare providers highlight early diabetes detection as the leading driver for HbA1c testing device adoption.
• Major Market Restraint: 48% of end-users identify high device costs as the primary restraint limiting adoption across low-income regions.
• Emerging Trends: 52% of hospitals are shifting toward point-of-care HbA1c testing devices for faster patient management.
• Regional Leadership: North America holds 41% of the global HbA1c testing device market share due to advanced healthcare infrastructure.
• Competitive Landscape: 37% of global device sales are controlled by the top three manufacturers, showing strong market consolidation.
• Market Segmentation: 54% of testing is conducted in hospitals, while 28% comes from homecare settings and 18% from diagnostic labs.
• Recent Development: 43% of manufacturers have launched compact HbA1c testing devices with integrated connectivity since 2023.

HbA1c Testing Device Market Trends

The HbA1c testing device market is undergoing significant transformation, influenced by innovations in technology, patient demand, and clinical practices. Globally, more than 75% of hospitals are incorporating point-of-care HbA1c testing systems, reducing turnaround times from 24 hours to less than 15 minutes. Portable HbA1c analyzers are being adopted by approximately 40% of outpatient clinics, highlighting a strong movement toward decentralized testing. Digital integration is another critical trend, with nearly 58% of newly launched HbA1c testing devices offering Bluetooth or cloud-based connectivity for streamlined reporting.

Additionally, rising health awareness is pushing self-monitoring practices, with 31% of diabetic patients showing preference for home-based HbA1c test kits in 2024. Laboratories continue to account for 46% of test volumes, but hospitals are increasingly focusing on compact devices to support high patient inflows. Personalized diabetes management is also shaping demand, with over 62% of endocrinologists recommending routine HbA1c testing every three months for chronic diabetes patients. The market is also seeing geographic diversification, as 49% of new device sales come from Asia-Pacific and Latin America, regions experiencing sharp increases in diabetes incidence. Together, these market trends are driving a more patient-centric, technologically advanced HbA1c testing landscape.

How is technological advancement driving the HbA1c Testing Device Market?

Technological advancements are significantly improving the efficiency and accessibility of HbA1c testing devices through faster analysis, enhanced accuracy, and digital connectivity. Modern point-of-care analyzers deliver results within minutes, while Bluetooth and cloud-enabled systems simplify data sharing with healthcare providers. Compact, portable devices designed for homecare and outpatient settings are expanding testing accessibility, supporting decentralized diabetes management and encouraging wider adoption across healthcare facilities.

HbA1c Testing Device Market Dynamics

DRIVER

"Increasing global diabetes prevalence."

The growing number of diabetic patients worldwide is the primary driver of HbA1c testing device adoption. The International Diabetes Federation estimates that 537 million adults live with diabetes as of 2021, projected to reach 643 million by 2030 and 783 million by 2045. In the USA alone, 1.4 million new cases are diagnosed each year, representing a strong demand base for HbA1c monitoring. More than 80% of clinicians rely on HbA1c testing for treatment adjustments, demonstrating its clinical significance. With 90% of diabetes cases categorized as type 2, where long-term monitoring is essential, the demand for HbA1c testing devices continues to grow.

RESTRAINT

"High device and consumable costs."

Despite growth opportunities, affordability remains a critical barrier. Approximately 48% of healthcare facilities in low-income countries report limited access to HbA1c testing devices due to high procurement and maintenance costs. Consumables such as test cartridges add recurring expenses, representing up to 35% of the total testing cost per patient. Rural healthcare centers, which serve 55% of diabetic patients in developing nations, often lack adequate funding to acquire modern analyzers. As a result, adoption rates remain lower in regions where per capita healthcare expenditure is below USD 1000 annually, directly restraining widespread market penetration.

OPPORTUNITY

"Expansion of point-of-care and home-based testing."

The rise of decentralized care creates strong growth opportunities for HbA1c testing device manufacturers. Around 31% of diabetic patients are already adopting home-based HbA1c kits, reflecting a significant shift in patient behavior. In rural Asia and Africa, mobile health clinics are introducing portable HbA1c analyzers, expanding access to more than 120 million underserved patients. Hospital procurement departments are prioritizing compact, digitally connected devices, with 43% of new contracts emphasizing connectivity features. The growing adoption of preventive health check-ups, covering 46% of urban adult populations in Asia-Pacific, further enhances the demand for rapid and accessible HbA1c testing.

CHALLENGE

"Quality control and regulatory compliance."

Ensuring test accuracy and meeting international regulatory standards is one of the biggest challenges for device manufacturers. Approximately 27% of small and mid-sized laboratories report inconsistencies in HbA1c readings due to lack of calibration, which impacts patient outcomes. Regulatory approvals are also becoming more stringent, with over 64% of manufacturers facing delays in product launches because of compliance testing. In emerging markets, where 55% of healthcare centers lack standardized quality protocols, inaccurate readings remain a concern. This challenge underscores the importance of robust R&D investment and adherence to quality assurance standards to ensure device reliability across all regions.

How is demand increasing for the HbA1c Testing Device Market?

Demand for HbA1c testing devices is increasing due to the rising global prevalence of diabetes and the growing emphasis on early diagnosis and continuous disease management. The increasing number of diabetic and prediabetic patients, coupled with greater awareness of routine glucose monitoring, is driving testing volumes. Healthcare providers are also adopting HbA1c testing as a standard diagnostic tool to improve treatment outcomes and reduce diabetes-related complications.

HbA1c Testing Device Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Point-of-Care (POC) Testing Devices

Point-of-care (POC) HbA1c testing devices are witnessing strong adoption due to their rapid turnaround time, portability, and ease of use in decentralized healthcare settings. These devices deliver results in less than 10 minutes, allowing healthcare professionals to make immediate treatment decisions and improve patient management during a single consultation. Their compact design, minimal sample preparation requirements, and user-friendly operation make them well suited for outpatient clinics, physician offices, community health centers, and primary care facilities. In 2024, POC devices accounted for 60% of the market, reflecting the growing preference for fast and accessible diabetes diagnostics.

The increasing burden of diabetes, expansion of preventive screening programs, and growing emphasis on early disease detection continue to support demand for POC testing devices. Technological advancements have improved device accuracy, connectivity, and data integration with electronic health records, making them valuable tools for routine diabetes monitoring. Rising healthcare accessibility in remote and underserved areas is further accelerating adoption of these portable diagnostic systems.

Laboratory-Based Testing Devices

Laboratory-based HbA1c testing devices remain essential for high-volume diabetes diagnostics due to their superior analytical accuracy, precision, and ability to process large batches of samples efficiently. Advanced laboratory analyzers are widely used in hospitals, diagnostic laboratories, and reference laboratories where standardized testing and consistent performance are critical. These systems support automated workflows, minimize operator variability, and deliver highly reliable results for diabetes diagnosis and long-term glycemic monitoring. The laboratory-based segment represented 40% of the market in 2024.

Continued investment in laboratory automation, quality assurance, and high-throughput diagnostic infrastructure is sustaining demand for these systems. Increasing healthcare expenditure, rising volumes of diabetes testing, and the need for standardized laboratory procedures continue to reinforce the importance of laboratory-based HbA1c analyzers, particularly in centralized healthcare settings where large patient populations are served daily.

BY APPLICATION

Hospitals

Hospitals represent the largest application segment for HbA1c testing devices, driven by routine diabetes diagnosis, inpatient care, chronic disease management, and regular follow-up assessments. Approximately 78% of multispecialty hospitals perform HbA1c testing as part of standard diabetes care protocols, ensuring effective monitoring of long-term blood glucose control. In 2024, hospitals accounted for 54% of total market demand, highlighting their central role in diabetes management.

The segment continues to benefit from increasing patient admissions, expanding healthcare infrastructure, and the growing prevalence of diabetes and related metabolic disorders. Hospitals are also adopting advanced diagnostic technologies and integrated laboratory systems to improve workflow efficiency, enhance patient outcomes, and support evidence-based treatment decisions across multiple clinical departments.

Homecare

Homecare has emerged as a rapidly growing application area as patients increasingly prefer convenient, accessible, and cost-effective solutions for managing diabetes outside traditional healthcare facilities. Easy-to-use HbA1c testing kits enable individuals to monitor long-term glucose control with greater independence while reducing the need for frequent hospital visits. The homecare segment captured 28% of the market in 2024, reflecting the growing acceptance of self-monitoring practices.

Growing awareness of diabetes prevention, increased adoption of remote patient monitoring, and the expansion of telehealth services are further supporting home-based HbA1c testing. Improvements in device simplicity, digital connectivity, and result accuracy have enhanced patient confidence, making homecare an increasingly important component of long-term diabetes management.

Other Diagnostic Facilities

Other diagnostic facilities, including specialized clinics, independent laboratories, research institutions, and outpatient diagnostic centers, play an important role in expanding access to HbA1c testing through preventive health programs and routine diagnostic services. These facilities provide convenient testing options for individuals undergoing regular health check-ups, diabetes risk assessments, and chronic disease monitoring. This segment accounted for 18% of the market in 2024.

The continued expansion of diagnostic networks, rising demand for preventive healthcare, and increasing awareness of early diabetes detection are driving growth in this application segment. Adoption of advanced diagnostic technologies, improved laboratory capabilities, and growing participation in community-based screening initiatives further strengthen the role of specialized diagnostic facilities in the overall HbA1c testing landscape.

Which segment is growing faster in the HbA1c Testing Device Market?

The Point-of-Care (POC) Testing Devices segment is growing faster because of its ability to provide rapid results, portability, and ease of use across decentralized healthcare settings. These devices support immediate clinical decision-making, reduce patient waiting times, and are increasingly used in outpatient clinics, physician offices, and primary healthcare centers. Their expanding role in remote and home-based testing continues to accelerate market growth.

HbA1c Testing Device Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America held the largest share of the HbA1c testing device market, accounting for 41% in 2024, supported by its advanced healthcare infrastructure, widespread diabetes screening programs, and high prevalence of diabetes. The region benefits from well-established reimbursement policies, strong adoption of both point-of-care and laboratory-based testing technologies, and a growing emphasis on early diagnosis and long-term glycemic monitoring. The increasing use of HbA1c testing in hospitals, diagnostic laboratories, physician offices, and homecare settings further strengthens market growth.

Rising healthcare expenditure, continuous technological advancements, and the integration of automated diagnostic solutions are driving the adoption of HbA1c testing devices across the region. The presence of leading medical device manufacturers, expanding preventive healthcare initiatives, and increasing patient awareness regarding routine diabetes management continue to reinforce North America's leadership in the global market.

EUROPE

Europe accounted for 28% of the global HbA1c testing device market in 2024, supported by well-established healthcare systems, comprehensive diabetes management programs, and widespread access to advanced diagnostic services. The region demonstrates strong adoption of laboratory-based analyzers due to their high analytical accuracy, while point-of-care testing continues to gain traction in outpatient settings because of its ability to deliver faster results and improve clinical efficiency.

Growing demand for early diabetes diagnosis, increasing adoption of automated laboratory technologies, and expanding preventive healthcare initiatives continue to drive market growth across Europe. Rising awareness of chronic disease management, favorable healthcare policies, and ongoing investments in diagnostic infrastructure are further supporting the adoption of HbA1c testing devices throughout the region.

ASIA-PACIFIC

Asia-Pacific represented 22% of the global HbA1c testing device market in 2024 and is emerging as one of the fastest-growing regions due to its large diabetic population and expanding healthcare infrastructure. Rapid urbanization, improving access to healthcare services, and increasing awareness of diabetes prevention have significantly boosted demand for HbA1c testing devices. Hospitals remain the primary testing centers, while independent diagnostic laboratories and community healthcare facilities are expanding access to routine diabetes screening.

Government healthcare initiatives, rising healthcare investments, and continuous improvements in diagnostic capabilities are accelerating market growth across the region. Increasing adoption of point-of-care technologies, expansion of private healthcare services, and growing emphasis on preventive health check-ups are expected to further strengthen demand for HbA1c testing devices.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for 9% of the global HbA1c testing device market in 2024, driven by the increasing prevalence of diabetes and ongoing expansion of healthcare infrastructure. Growing awareness of diabetes-related complications, improving access to diagnostic services, and rising investments in healthcare modernization have contributed to higher adoption of HbA1c testing devices. Hospitals, specialized diabetes centers, and diagnostic clinics remain the primary end users of these systems.

The market is further supported by government-led public health initiatives, expanding private healthcare networks, and increasing emphasis on preventive disease management. Improvements in laboratory capabilities, greater availability of point-of-care testing solutions, and rising demand for routine diabetes monitoring continue to create significant growth opportunities across the region.

Which region dominates the HbA1c Testing Device Market?

North America dominates the HbA1c testing device market, accounting for 41% of the global market in 2024. The region benefits from advanced healthcare infrastructure, widespread diabetes screening programs, strong reimbursement policies, and high adoption of both laboratory-based and point-of-care testing technologies. Continuous technological innovation, increasing healthcare expenditure, and growing awareness of diabetes management further strengthen the region's leadership in the global market.

List of Top HbA1c Testing Device Companies

• HUMAN
• Trinity Biotech
• Ceragem Medisys Inc
• Abbott
• SEKISUI MEDICAL CO., LTD.
• SAKAE CO. LTD.
• Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.
• Menarini Diagnostics s.r.l
• Siemens Healthineers AG

Top Two Companies with Highest Market Share:

• Abbott controls approximately 12% of the global HbA1c testing device market share in 2024, driven by its wide adoption of point-of-care systems in North America and Asia.
• Hoffmann-La Roche Ltd holds nearly 11% market share globally, with strong dominance in Europe where its laboratory-based analyzers account for 39% of hospital installations.

Investment Analysis and Opportunities

Investment activity in the HbA1c testing device market has intensified as healthcare providers and manufacturers respond to increasing global diabetes prevalence. In 2023–2024, more than 1.2 billion USD in private equity and venture capital was directed toward diagnostic device companies focusing on point-of-care HbA1c testing. Approximately 47% of these investments targeted Asia-Pacific startups developing portable analyzers to serve large urban and rural populations. Hospitals and diagnostic labs represent a major investment channel, with 56% of procurement budgets in North America and Europe allocated to diagnostic devices, including HbA1c analyzers.

Strategic partnerships between manufacturers and healthcare networks are expanding, with 32% of device companies entering long-term supply contracts with large hospital chains. Government support also drives opportunities, as 41% of diabetes-focused public health initiatives across Asia and Africa now include HbA1c testing as a key component. Investors are also eyeing homecare opportunities, as 28% of diabetic patients globally show preference for self-monitoring kits. This shift has led to 19% growth in direct-to-consumer device distribution channels in 2024 alone.

New Product Development

The HbA1c testing device market is experiencing a surge in new product development, with manufacturers focusing on speed, portability, and digital integration. Between 2023 and 2024, nearly 43% of newly launched HbA1c devices featured Bluetooth or Wi-Fi connectivity to allow seamless data transfer into electronic health records. Compact analyzers capable of delivering results in under 5 minutes are now used by 34% of outpatient clinics, reducing patient waiting times dramatically. Manufacturers are also focusing on miniaturization, with 27% of new HbA1c analyzers designed specifically for homecare usage. These kits use finger-prick blood samples of less than 5 microliters, a significant reduction compared to traditional laboratory devices requiring 50–100 microliters.

Cloud-enabled devices are expanding rapidly, with 39% of newly launched systems allowing remote monitoring by healthcare providers. Customization is another focus area, as 31% of new systems integrate multi-test panels that combine HbA1c testing with lipid and glucose monitoring. This approach supports comprehensive diabetes care in a single device. Sustainability is emerging as well, with 22% of manufacturers introducing recyclable test cartridges to reduce clinical waste. These advancements underline the industry’s strong emphasis on patient convenience, clinical accuracy, and cost-effective HbA1c testing solutions for diverse healthcare settings.

Five Recent Developments

• Abbott introduced a next-generation handheld HbA1c analyzer in 2024, offering results in 3.5 minutes with connectivity to cloud-based patient portals.
• Siemens Healthineers expanded its product line in 2023 with a high-throughput HbA1c laboratory system capable of processing 250 samples per hour.
• Bio-Rad Laboratories launched an AI-driven calibration technology in 2024, improving test accuracy by 18% in clinical environments.
• Roche announced in 2025 the integration of HbA1c testing into its existing diagnostic platforms, allowing combined testing with glucose and lipid panels.
• Trinity Biotech introduced a low-cost HbA1c kit in 2023, specifically targeting rural healthcare centers in Asia and Africa, reducing per-test costs by 27%.

Report Coverage of HbA1c Testing Device Market

The HbA1c Testing Device Market Report provides a comprehensive analysis of industry performance, covering market size, share, segmentation, and regional outlook across 2023–2034. The scope includes both point-of-care devices and laboratory-based analyzers, with detailed insights into applications across hospitals, homecare, and diagnostic laboratories. More than 10 leading companies, including Abbott, Roche, Siemens Healthineers, and Bio-Rad Laboratories, are assessed in terms of competitive landscape, product offerings, and innovation strategies.

The report also examines market dynamics in depth, highlighting key drivers such as rising diabetes prevalence, restraints like high device costs, opportunities in decentralized testing, and challenges related to regulatory compliance. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, representing over 537 million diabetes patients globally in 2021, projected to rise to 643 million by 2030.

HbA1c Testing Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 158.1 Million in 2026
Market Size Value By	USD 340.79 Million by 2035
Growth Rate	CAGR of 8.91% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Point-of-care (POC) Testing Devices Laboratory-based Testing Devices By Application : Hospital Homecare Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample